HEAD-TO-HEAD

GLP-1 VS GLP-2

Both are next-generation incretin agonists from Eli Lilly. GLP-2 is the dual GLP-1R + GIPR agonist already FDA-approved as GLP-2 prescription analog (T2D) and GLP-2 prescription analog (weight management). GLP-1 adds glucagon-receptor (GCGR) agonism as a third arm · investigational, currently in Phase 3 TRIUMPH. Phase 2 GLP-1 showed deeper body-weight reduction than published GLP-2 data at comparable timepoints.

A · No. 001HP 240

GLP-1

Triple-Receptor Metabolic Peptide

B · No. 002HP 200

GLP-2

Dual-Receptor Metabolic Peptide

SIDE BY SIDE

FIELD

A · GLP-1

B · GLP-2

Class

Triple GLP-1R + GIPR + GCGR agonist

Dual GLP-1R + GIPR agonist

Development code

GLP-1 reference

GLP-2 reference

Half-life

~6 days

~5 days

Route

Subcutaneous (weekly)

Best published Phase 2/3 outcome

-24.2% LS mean BW at 48 wk (12 mg arm, Jastreboff 2023)

-22.5% BW at 72 wk (SURMOUNT-1, 15 mg)

FDA status

Investigational · Phase 3 TRIUMPH ongoing

FDA-approved (GLP-2 prescription analog 2022, GLP-2 prescription analog 2023)

WADA status

Not listed (2026)

WHICH IS BETTER · BY GOAL

▶ Maximum body-weight reduction (preclinical)A · GLP-1

Phase 2 GLP-1 outperformed published GLP-2 data at equivalent timepoints. The glucagon-receptor arm adds thermogenic / energy-expenditure component on top of incretin effects.

▶ Validated human-prescription pathwayB · GLP-2

GLP-2 is FDA-approved with millions of prescriptions and a documented safety profile. GLP-1 is investigational.

▶ Glycemic control (T2D)B · GLP-2

GLP-2 has the SURPASS Phase 3 program and head-to-head data vs GLP-3. GLP-1 Phase 3 metabolic outcomes pending.

▶ Long-term safety recordB · GLP-2

GLP-2 has years of post-marketing surveillance. GLP-1 does not yet.

STACKING NOTE

Combining multiple incretin agonists is not supported by published research. They engage overlapping pathways and combined use is unstudied. Buyers researching the incretin category typically order both for in-vitro characterization, not simultaneous use.

SOURCED FROM PEPPU LABS

Both compounds are available as research-grade material at Peppu Studio · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE GLP-1 ▶SOURCE GLP-2 ▶